- Home
- AIRT vs MREO Comparison
AIRT vs MREO Comparison
Compare AIRT & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRT | MREO |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United Kingdom |
| Employees | 646 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.8M | 52.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | AIRT | MREO |
|---|---|---|
| Price | $22.30 | $0.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 2.9K | ★ 1.8M |
| Earning Date | 02-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.15 | $0.20 |
| 52 Week High | $26.70 | $2.94 |
Technical Indicators
Market Signals| Indicator | AIRT | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | 49.24 |
| Support Level | $20.85 | $0.21 |
| Resistance Level | $23.82 | $0.36 |
| Average True Range (ATR) | 0.70 | 0.03 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 72.58 | 55.27 |
Price Performance
Historical ComparisonAbout AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).